Who are Celularity Inc.'s main suppliers?

Celularity Inc. (CELU) key suppliers include: HELENA-GLOBAL-INVESTMENT-OPPORTUNITIES-1-LTD, SENIOR-NOTE-INVESTORS, INVESTOR, Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc. and 6 more. View the full supplier network at chainsifter.com/chain/CELU.

Who are Celularity Inc.'s major customers?

Celularity Inc. (CELU) key customers include: BIOCELLGRAFT-INC, DEFEYE-INC, NEXGEL-INC, Allogene Therapeutics, Inc., Allogene Therapeutics, Inc. and 18 more. View the full customer network at chainsifter.com/chain/CELU.

What sector is Celularity Inc. in?

Celularity Inc. (CELU) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Celularity Inc. Suppliers, Customers & Supply Chain (CELU)

11Suppliers

23Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Celularity Inc. (CELU) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

38Total relationships

4Distinct source URLs

10High confidence

0.761Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Celularity Inc. Suppliers

Ticker	Name	Confidence	Evidence
HELENA-GLOBAL-INVESTMENT-OPPORTUNITIES-1-LTD	HELENA-GLOBAL-INVESTMENT-OPPORTUNITIES-1-LTD	90%	Helena delivered an exchange notice pursuant to which Helena elected to exchange shares of the Company's Series A Convertible Preferred Stock for a Convertible Promissory Note
SENIOR-NOTE-INVESTORS	SENIOR-NOTE-INVESTORS	90%	The Company issued Senior Notes to one or more Participation Purchasers and together with the Investor, the 'Senior Note Investors'
INVESTOR	INVESTOR	80%	The Company entered into a board observer rights agreement with the Investor granting the Investor the right to designate one non-voting observer
ALLO	Allogene Therapeutics, Inc.	72%	Reciprocal relationship from ALLO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ALLO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ALLO g…
ATRA	Atara Biotherapeutics, Inc.	72%	Reciprocal relationship from ATRA graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ATRA graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ATRA g…
CRSP	CRISPR Therapeutics AG	72%	Reciprocal relationship from CRSP graph: Reciprocal relationship from CELU graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from CELU graph: Reciprocal relationship from CRSP g…
DTIL	Precision BioSciences, Inc.	72%	Reciprocal relationship from DTIL graph: Reciprocal relationship from CELU graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from CELU graph: Reciprocal relationship from DTIL g…
IPSC	Century Therapeutics, Inc.	72%	Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU graph: Reciprocal relationship from IPSC g…
NTLA	Intellia Therapeutics, Inc.	72%	Reciprocal relationship from NTLA graph: Reciprocal relationship from CELU graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from CELU graph: Reciprocal relationship from NTLA g…
ORGO	Organogenesis Holdings Inc.	72%	Reciprocal relationship from ORGO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ORGO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ORGO g…
SGMO	Sangamo Therapeutics, Inc.	72%	Reciprocal relationship from SGMO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from SGMO g…

Celularity Inc. Customers

Ticker	Name	Confidence	Evidence
BIOCELLGRAFT-INC	BIOCELLGRAFT-INC	92%	In December 2025, we entered into an amended Sublicense and Marketing Agreement with BioCellgraft, Inc., to develop and commercialize certain of our advanced biomaterial products under private label …
DEFEYE-INC	DEFEYE-INC	92%	In October 2025, we entered into a collaboration and license agreement with Defeye, Inc. to develop, manufacture, and commercialize certain of our advanced biomaterial products for ophthalmic applica…
NEXGEL-INC	NEXGEL-INC	92%	the Amendment provides that: (i) the aggregate consideration payable to the Company under the Agreement is $13.3 million, consisting of an upfront cash payment of $8.3 million on the transaction comm…
ALLO	Allogene Therapeutics, Inc.	72%	. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p…
ALLO	Allogene Therapeutics, Inc.	72%	Reciprocal relationship from ALLO graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived alloge…
ATRA	Atara Biotherapeutics, Inc.	72%	. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p…
ATRA	Atara Biotherapeutics, Inc.	72%	Reciprocal relationship from ATRA graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ATRA graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent …
CRSP	CRISPR Therapeutics AG	72%	. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p…
CRSP	CRISPR Therapeutics AG	72%	Reciprocal relationship from CRSP graph: Reciprocal relationship from CELU graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from CELU graph: Reciprocal relationship from CRSP g…
DTIL	Precision BioSciences, Inc.	72%	. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p…
DTIL	Precision BioSciences, Inc.	72%	Reciprocal relationship from DTIL graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived alloge…
IPSC	Century Therapeutics, Inc.	72%	Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU graph: Reciprocal relationship from IPSC graph: Reciprocal relationship from CELU graph: Reciprocal relationship from IPSC g…
IPSC	Century Therapeutics, Inc.	72%	. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p…
NTLA	Intellia Therapeutics, Inc.	72%	Reciprocal relationship from NTLA graph: Reciprocal relationship from CELU graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent …
NTLA	Intellia Therapeutics, Inc.	72%	. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p…
ORGO	Organogenesis Holdings Inc.	72%	Reciprocal relationship from ORGO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from ORGO graph: Reciprocal relationship from CELU graph: . Our pipeline reflects our intent …
ORGO	Organogenesis Holdings Inc.	72%	. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p…
REGN	Regeneron Pharmaceuticals, Inc.	72%	. Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories of its consolidated statement of operations and comprehensive loss: Schedu…
REGN	Regeneron Pharmaceuticals, Inc.	72%	Reciprocal relationship from REGN graph: Reciprocal relationship from CELU graph: . Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense cat…
SGMO	Sangamo Therapeutics, Inc.	72%	Reciprocal relationship from SGMO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from CELU graph: Reciprocal relationship from SGMO g…
SGMO	Sangamo Therapeutics, Inc.	72%	. Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could p…
SOR	Source Capital	62%	Reciprocal relationship from SOR graph: Reciprocal relationship from CELU graph: Reciprocal relationship from SOR graph: Reciprocal relationship from CELU graph: Reciprocal relationship from SOR grap…
SORRENTO-THERAPEUTICS-INC	SORRENTO-THERAPEUTICS-INC	62%	ults, revenue or specific net income that justifies such transaction. 29 We may not realize the benefits of acquired assets or other strategic transactions. We actively evaluate various strategic tra…

Celularity Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CELU-DEBT-8582	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2025-12-31.
CELU-DEBT-8581	Warrants outstanding: 892856	90%	xbrl warrant detail from xbrl 2025-12-31.
CELU-DEBT	Debt stack $74.7M	90%	Market cache reports total debt of $74.7M.

Celularity Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Celularity Inc..

Celularity Inc. Ownership

Holder	Name	Confidence	Evidence
CELU-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 38 tracked holders.

Celularity Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CLLS	Cellectis S.A.	100.00	2
KLRS	Kalaris Therapeutics, Inc.	100.00	2
ARTV	Artiva Biotherapeutics, Inc.	100.00	2
BDRX	Biodexa Pharmaceuticals Plc	100.00	2
FISI	Financial Institutions, Inc.	100.00	2
IPSC	Century Therapeutics, Inc.	100.00	1	['customer', 'supplier']
CRBU	Caribou Biosciences, Inc.	100.00	2
ACET	Adicet Bio, Inc.	100.00	2
LGND	Ligand Pharmaceuticals Incorporated	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	1	['customer', 'supplier']
DTIL	Precision BioSciences, Inc.	100.00	1	['customer', 'supplier']
GDTC	CytoMed Therapeutics Limited	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	1	['customer', 'supplier']
AZN	AstraZeneca PLC	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	1	['customer']
EDSA	Edesa Biotech, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
CRSP	CRISPR Therapeutics AG	100.00	1	['customer', 'supplier']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
TKPHF	Takeda Pharmaceutical Company Limited	100.00	2

Celularity Inc. Supply Chain